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Abstract: Individuals in the early phases of psychotic illness have disturbed metacognitive 
capacity, which has been linked to a number of poor outcomes. Little is known, however, 
about the neural systems associated with metacognition in this population. The purpose of 
this study was to elucidate the neuroanatomical correlates of metacognition. We anticipated 
that higher levels of metacognition may be dependent upon gray matter density (GMD) of 
regions within the prefrontal cortex. Examining whole-brain structure in 25 individuals 
with early phase psychosis, we found positive correlations between increased medial 
prefrontal cortex and ventral striatum GMD and higher metacognition. These findings 
represent an important step in understanding the path through which the biological 
correlates of psychotic illness may culminate into poor metacognition and, ultimately, 
disrupted functioning. Such a path will serve to validate and promote metacognition as a 
viable treatment target in early phase psychosis. 
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1. Introduction 
Schizophrenia is a chronic and disabling psychiatric disorder [1], affecting greater than 20 million 
individuals worldwide [2]. It is associated with compromised daily functioning, as well as severe 
symptoms such as hallucinations, delusions, disordered thinking and odd behavior. Metacognitive 
dysfunction has gained increasing recognition for its importance to clinical course and outcome in 
schizophrenia and related psychotic illnesses. Indeed, impaired metacognition functions as an 
important and independent predictor of psychosocial function over time [3]. Although metacognition 
broadly refers to the process of thinking about cognitive states, it can be thought of as a spectrum of 
mental activities ranging from discrete (recognition of thoughts, feelings, and basic judgment) to more 
synthetic capacities. Because the neural correlates of synthetic metacognition have yet to be 
investigated, the present study focuses on this form of metacognition that, importantly, represents the 
ability to form and utilize integrated, complex mental representations of the self, others, and events in 
order to respond to life challenges [4,5]. 
Individuals with prolonged psychosis have compromised metacognitive capacity which has been 
linked to symptoms [5–12], learning difficulties [13], reduced motivation [14] and poor psychosocial 
functioning [10,15–17]. Importantly, these findings have recently been extended to include individuals 
in the early phase of psychosis (EPP), suggesting that metacognitive deficits emerge early in the 
disease process and may represent a risk factor for poorer outcomes [18–21]. Investigations focused on 
EPP capitalize upon the unique opportunity to study underlying illness pathophysiology with the goal 
of ultimately developing novel therapeutics and preventing the negative outcomes associated with 
chronic psychotic illness [22,23]. In particular, individuals with EPP typically have fewer comorbidities, 
shorter durations of antipsychotic treatment, and possibly lower severity of illness. Despite the advantages 
of studying EPP and the deleterious impact of impaired metacognition, our understanding of the neural 
substrates underlying metacognition in this population is limited. Such data is likely to be vital to 
identifying biological mechanisms of metacognition in EPP, informing the development of novel 
therapeutics that can ameliorate present and future dysfunction, and in providing an objective measure 
of cortical reorganization that can be used to monitor the progress and outcome of interventions [24]. 
Advances in technology over the last several decades have enabled increased ability to understand 
psychosis, moving across levels of analysis from basic science and the study of molecules to 
investigations of higher order disturbances in human consciousness. The purpose of this study was to 
elucidate the neural substrates underlying metacognitive capacity in EPP. One possible route to 
studying neural correlates of metacognition is to employ magnetic resonance imaging (MRI) 
techniques. Neuroimaging data allow for the examination of psychosis as a brain disorder with altered 
structure and function [25,26]. We performed a whole-brain grey matter density (GMD) analysis via 
voxel-based morphometry (VBM) to examine specific metacognition-morphometry associations. 
Volumetric measurements, such as VBM, are popular whole-brain analytical methods that can reveal 
regional brain abnormalities or associations with variables of interest, in an unbiased manner [27,28]. 
Meta-analyses, including studies of GMD in EPP and prolonged psychosis samples, have consistently 
demonstrated reduced volume in several regions. The most profoundly affected of these areas include 
the inferior and middle frontal cortices, anterior cingulate cortex, and insula [29–32]. Studies 
specifically examining discrete metacognitive processes suggest that areas of prefrontal cortex (PFC) 
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may subserve a number of domains of metacognition [33,34]. Therefore, in the present investigation, 
we hypothesized that higher levels of metacognition would be dependent upon gray matter density 
(GMD), particularly in the prefrontal cortex. 
2. Results and Discussion 
The socio-demographic characteristics and average scores for measures of symptoms and 
metacognition are reported in Table 1. No associations with other demographic or symptom measures 
were revealed. 
Table 1. Participant characteristics. 
Characteristic M SD N (%) 
Male   20 (80%) 
African American   18 (72%) 
Age (years) 23.2 4.4  
Education    
Middle/junior high school   2 (8%) 
High school, no degree   6 (24%) 
High school, degree   7 (28%) 
Some university courses   7 (28%) 
Associate’s degree   1 (4%) 
Bachelor’s degree   2 (8%) 
SES a 2.7 1.1  
Age of onset of psychosis 21.0 4.8  
Duration of treatment (months) b 15.2  11.7  
Antipsychotic drug exposure c 164.1 187.5  
CGI-S 3.0 0.8  
PANSS Total 51.4 13.3  
Positive 12.0 4.9  
Negative 14.7 5.2  
Disorganized 15.1 5.1  
MAS-A Total 11.4 5.0  
Self Reflectivity 4.5 1.8  
Other Reflectivity 2.4 1.2  
Decentration 0.6 0.7  
Mastery 4.0 1.7  
a SES (socioeconomic status) measured using the Hollingshead Two Factor Index of Social Position 
(Hollingshead & Redlich, 1958), which is comprised of an occupational and educational scale and ranges 
from 1 to 5 (higher index = higher SES); b calculated as number of months from date of first treatment for 
psychosis of date of imaging; c chlorpromazine (CPZ) equivalents in grams; CGI-S = Clinical Global 
Impression-Severity (range: 1 to 7, higher scores indicate worse global functioning); PANSS = Positive and 
Negative Syndrome Scale; MAS-A = Metacognitive Assessment Scale Abbreviated (a total score of 
metacognitive capacity); M = mean; SD = standard deviation. 
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Metacognition and Whole Brain Gray Matter Density 
Voxel based morphometry (VBM) analyses indicated that metacognition was positively correlated 
to gray matter density (GMD) in several locations (Table 2), with higher metacognition related to 
higher GMD. In the primary analysis, metacognition was associated with bilateral dorsal lateral 
(DLPFC) and medial (mPFC) prefrontal cortices, ventral striatum (VS), precentral gyrus, and anterior 
cingulate cortex (ACC). Correlations between the related brain areas and total metacognition and 
specific metacognitive domains are listed in Table 3. 
By including the Positive and Negative Syndrome Scale (PANSS) negative symptom cluster as a 
regressor, we demonstrated that the relationships of mPFC and VS with metacognition were not better 
accounted for by the association between total metacognition and negative symptoms (Table 4). 
Significant positive correlations were found to persist for the right mPFC (Table 5 and Figure 1) and 
VS (Table 5). These relationships were again positive suggesting increased GMD in these areas was 
associated with higher metacognition (Figure 2). 
Table 2. Whole-brain gray matter volume analysis. 
Region R/L BA MNI Coordinates (x, y, z)
t-Value  
(Peak Voxel) 
Cluster Size 
(Voxels) 
Dorsal Lateral Prefrontal Cortex L 10 −32, 47, 7 6.22 692 
Dorsal Lateral Prefrontal Cortex R 10/11 27, 34, 24 6.00 589 
Medial Prefrontal Cortex R 10/11 18, 62, 7 5.75 1684 
Ventral Striatum R – 10, 16, −6 4.77 611 
Precentral Gyrus R 4 63, −1, 45 4.44 747 
Anterior Cingulate Cortex L 32 −3, 36, 27 4.39 860 
Voxel-level p < 0.005 corrected at cluster-level to p < 0.05; BA = Brodmann area; MNI = Montreal 
Neurological Institute; R = Right; L = Left. 
Table 3. Correlational analysis of gray matter density (GMD) in significant clusters and metacognition. 
Region MAS-A Self-Reflect Other-Reflect Mastery 
L.DLPFC 0.455 * 0.472 * 0.274 0.522 ** 
R.DLPFC 0.650 ** 0.686 ** 0.462 * 0.640 ** 
mPFC 0.565 ** 0.606 ** 0.411 * 0.572 ** 
VS 0.506 ** 0.405 * 0.420 * 0.524 ** 
Precentral Gyrus 0.260 0.275 0.087 0.312 
ACC 0.568 ** 0.599 ** 0.455 * 0.563 ** 
All values represent Pearson correlation coefficients (r). GMD = gray matter density; MAS-A = 
Metacognitive Assessment Scale Abbreviated (a total score of metacognitive capacity); L.DLFPF = dorsal 
lateral prefrontal cortex; R.DLPFC = dorsal lateral prefrontal cortex; mPFC = medial lateral prefrontal 
cortex; VS = ventral striatum; ACC = anterior cinculate cortex; * p < 0.05; ** p < 0.01. 
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Table 4. Whole-brain gray matter volume results, covarying for PANSS negative scores. 
Region R/L BA 
MNI Coordinates 
(x, y, z) 
t-Value (Peak Voxel) Cluster Size (Voxels) 
Medial prefrontal cortex R 9/10 18, 63, 7 4.07 2482 
Voxel-level p < 0.005 corrected at cluster-level to p < 0.05; BA = Brodmann area; MNI = montreal 
neurological institute; R = right; L = left; PANSS = Positive and Negative Syndrome Scale. 
Table 5. Correlational analysis of GMD in significant clusters (covarying for PANSS 
negative scores) and metacognition. 
Region MAS-A Self-Reflect Other-Reflect Mastery 
mPFC 0.566 ** 0.605 ** 0.424 * 0.564 ** 
VS 0.464 * 0.451 * 0.367 0.513 ** 
All values represent Pearson correlation coefficients (r). GMD = gray matter density; MAS-A = Metacognitive 
Assessment Scale Abbreviated (a total score of metacognitive capacity); * p < 0.05, ** p < 0.01. 
 
Figure 1. Illustration of significant positive relationship between the medial prefrontal 
cortex cluster and total metacognition score. Areas highlighted in red indicate regions of 
positive association. 
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Figure 2. Scatterplots of GMD in significant clusters and group total metacognition score. 
Taken together, the above findings support our hypothesis that metacognition as measured by the 
Metacognitive Assessment Scale Abbreviated (MAS-A) is subserved by specific neuroanatomical 
structures. Specifically, even after controlling for negative symptoms [5], higher metacognition scores 
were linked to greater GMD in both right mPFC and ventral striatum. Though the methods and data 
presented here preclude causal inference, the findings do suggest that these areas likely represent 
neuroanatomical sites required for metacognitive processing in EPP. 
The implication of mPFC in synthetic metacognition is consistent with a number of studies that 
suggest mPFC may play an important role in metacognitive processes [33]. These results are also 
consistent with widely accepted research that has shown that the mPFC plays an important part in self 
referential [35] and socio-emotional processing [36]; functions necessary for forming and integrating 
complex ideas about the self and others. Self referential processing involves linking information to be 
remembered with knowledge of the self [35,37]. Recent evidence also suggests however that the 
functions of the mPFC may be more clearly defined by domain and the area within mPFC [34]. Moran 
and colleagues [38] showed that the dorsal mPFC was engaged when participants thought about 
characteristics relevant to both self and others, while ventral mPFC was specifically engaged when 
individuals were cued with information specific to themselves. In the present study, metacognition was 
not related to a specific area of mPFC. One potential explanation for our more inclusive finding is that 
synthetic metacognition requires integration of knowledge of the self and others in order to form 
meaningful ideas about personal and social experiences. 
The second finding, that total metacognition was associated with GMD of the ventral striatum (VS), 
was not an a priori prediction but nonetheless may have important implications. The VS is thought to 
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consist primarily of the nucleus accumbens and olfactoray tubercle [39], with the nucleus accumbens 
often considered the key structure [40]. The striatum is densely innervated by dopaminergic 
connections [41,42] with distinct functionality. Data drawn from the Parkinson’s disease literature, for 
instance, suggests that dopamine dysregulation correlates with aberrant patterns of neural activity in 
cortical networks involving VS [43]. The VS specifically receives afferent input from the ventral 
tegmental area with reciprocal connections with cortical (anterior cingulate, orbitofrontal, and anterior 
temporal) and limbic (hippocampus, insula, amygdala, hypothalamus) regions [43]. Such connections 
are thought to be involved in a number of cognitive processes that may be vital to metacognition [5], 
including associating events across time, orientation, implicit and explicit learning, temporal binding 
of experience, and assessment of the motivational state of an individual [43]. Imaging studies suggest 
that VS is also differentially active during novelty or salience tasks [44], as well as those involving 
social rewards [45] and encoding facial emotion [46,47]. These processes could be expected to support 
the complex integration of personal and social information as needed for metacognition. Moreover, if 
these functions of the VS were compromised due to reduced GMD, it could provide a neurobiological 
basis for the supposition that loss of metacognitive capacity leaves persons without a larger sense of 
the meaning of past and current events and a compromised ability to manage life challenges. Further 
research, using functional measures, will be needed however to elucidate the potential role of the 
striatum and connected structures in metacognitive processing. 
As mentioned above, individuals in the early phase of psychosis appear to experience metacognitive 
deficits [18,19] that may even exceed what is observed in the later phases of illness [20], but there is a 
paucity of data about possible neural substrates. An important implication of the present work is that, 
by furthering understanding of the neurobiological substrates of metacognition in EPP, a novel early 
intervention target could be validated and promoted [48,49]. For instance, a number of neuroimaging 
studies have shown that psychological interventions for psychosis, such as cognitive remediation and 
cognitive behavior therapy, result in functional normalization of fronto-cortical areas [24]. Continued 
study of such relationships seems particularly vital in EPP since early intervention may reduce chronic 
dysfunction and improve outcomes [22,23]. 
Early scholars described psychosis as an interruption in goal directed behavior secondary to a 
complex, biologically based decomposition and unbinding of associations that collapsed higher order 
understanding of self and others [50]. However, over several decades a more detailed understanding of 
the sequence of events which converge in psychotic illness to result in dysfunction has emerged. 
Genetic vulnerabilities for psychosis have, for instance, been linked with abnormalities in brain 
development, which are reflected in specific cognitive deficits [51–53]. Albeit simplified, we propose 
a model that draws from this work and also offers a possible path from aberrant brain structure 
(reduced GMD in mPFC and VS) to the dysfunction associated with EPP (see Figure 3). Such a model, 
if supported with further research, would represent another step in moving toward understanding  
the neuroantomical underpinnings of higher order metacognitive process that are directly linked to 
functioning and outcomes for individuals with psychotic illness [3]. 
A number of caveats should be considered when interpreting the findings of this study. First, the 
relatively modest sample used here included primarily young, African American males within 5 years 
of initial diagnosis of psychotic illness. It is therefore possible that a sample with more females or 
individuals of varied ethnic backgrounds, or perhaps even those experiencing their very first acute 
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episode of illness, may have different results. Because there was no comparison group in this study, it 
is also difficult to say exactly how the observed metacognitive deficits are related to structural 
abnormalities. It is possible that the observed link between the study variables was due to some other 
unforeseen population-specific factor. The current study did account for factors such as antipsychotic 
drug exposure or current symptomatology and other potential confounds related to volumetric 
measurements such as VBM (registration differences, size of the smoothing kernel, shape differences 
that arise from systematic registration errors during spatial normalization, and image noise) are 
difficult to control. In terms of VBM, blurring is 3 dimensional and therefore does not respect 
boundaries along tissue classes, leading to increased probability of either diluting existing signal or 
misinterpreting boundary shift as signal. Additionally, only a single imaging analysis technique was 
employed in the present study. Other techniques, such as Diffusion Tensor Imaging (DTI) analysis 
may yield insight into to how white matter integrity affects metacognitive capacity. 
In addition to these limitations, a number of questions remain. Medial PFC and ventral striatum 
GMD is linked to metacognitive capacity, but exactly how does this occur? Do such neurobiological 
alterations mediate the impact of metacognitive deficits on other aspects of the illness and, ultimately, 
behavior? Do the structures that subserve metacognition also play a role in other important 
psychological phenomenon, such as poor awareness of illness that are thought to be linked to 
metacognitive processing? Answers to these and other questions seem essential in order to develop fully 
elucidate neural correlates and treatments that adequately intervene at the level most proximate to function. 
 
Figure 3. A path from gene to brain to dysfunctional behavior in schizophrenia. 
3. Experimental Section 
3.1. Study Participants 
Twenty-five individuals with EPP were recruited through the Indiana University Psychotic 
Disorders Program, within the Indiana University School of Medicine. All study procedures were 
completed via two concurrent studies both approved by the Indiana University Institutional Review 
Board, protocol numbers 1112007648 (initially approved 9 February 2012) and 1011002975 (initially 
approved 14 September 2010). After receiving an explanation of study procedures, subjects gave  
their written informed consent prior to enrollment. At a baseline visit, demographic information and 
medical history were recorded. Patients were ages 18–35, within the first five years of psychotic illness 
onset, including diagnoses of schizophrenia, schizophreniform disorder, schizoaffective disorder, or 
Psychotic disorder not otherwise specified, as confirmed by a trained psychiatrist or psychologist via 
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clinical interview and/or administration of the Structured Clinical Interview for Diagnosis (SCID) for 
the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) [54]. All patients were on 
antipsychotic medication at the time of testing (mean chlorpromazine equivalent = 164.1, standard 
deviation = 187.5). Exclusionary criteria included active substance abuse or dependence within three 
months of testing, a history of total IQ less than 70, as documented in the medical record, or MR 
incompatibility. Further details are listed in Table 1. 
3.2. Metacognition and Symptom Assessment 
3.2.1. Measurement of Metacognition 
Metacognitive capacity was assessed in a two-step process. First a narrative about self and illness 
was elicited using the Indiana Psychiatric Illness Interview (IPII) [55]. The IPII is a semi-structured 
interview which generally takes between 30 and 60 min to complete. Responses are audio recorded, 
transcribed, and then rated by trained investigators using the Metacognition Assessment Scale 
Abbreviated (MAS-A) [10]. The MAS-A was cooperatively developed with the authors of the  
MAS [56] in order to develop an instrument to assess metacognition as manifest in personal narratives. 
Good inter-rater reliability (intraclass correlation = 0.82) and validity has been presented  
elsewhere [3]. The MAS-A includes subscales in several domains: “Understanding of one’s own 
mind” or the comprehension of one’s own mental states (range 0—no awareness of own mental states, 
to 9—recognizes thoughts and emotions across larger life story); “Understanding of others’ minds” 
(range 0—no awareness of others mental states to 7—complete description of others, across larger life 
story); “Decentration” or the ability to see the world as existing with others having independent 
motives (range 0—views the self as the center of all events, to 3—understands others have separate, 
independent lives from individuals and that things unfold as a result of larger, complex factors); and 
“Mastery” or the ability to work through one’s representations and mental states to implement 
effective action strategies in order to accomplish cognitive tasks or cope with problematic mental 
states (range 0—unaware of own psychological problem, to 9—able to respond to psychological 
problems based on knowledge of larger life understanding of self and others). For the purposes of this 
study, the domains were not only examined independently but also combined to form a total score for 
metacognitive capacity (range 0 to 28). Higher scores indicate higher metacognition. 
3.2.2. Measurement of Symptoms 
Symptoms were assessed via the Positive and Negative Syndrome Scale (PANSS), which is a  
30-item scale designed to be completed by a trained rater at the conclusion of an interview and  
chart review [57]. Previous work has shown that MAS-A ratings, and thus metacognitive capacity,  
are correlated with levels of negative symptomatology [9]. Therefore, the Negative subscale, of the 
PANSS factor analytically derived components [58], was utilized in statistical analyses. All PANSS 
assessments were completed by well-trained, supervised masters-level clinicians with adequate  
inter-rater reliability (intraclass correlations: 0.85 to 0.93). 
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3.3. Neuroimaging Acquisition and Analysis 
Structural Magnetic Resonance Imaging (MRI) Data Acquisition and Analysis 
At the imaging visit, patients underwent a magnetic resonance imaging (MRI) scan on a 3T Tim 
Trio scanner (Siemens, Erlangen, Germany) with a 32-channel phased array head coil. Brain  
structure was characterized with a high-resolution T1-weighted whole-brain magnetization prepared 
rapid gradient echo (MPRAGE) scan with the following parameters: 160 3D sagittal slices,  
echo time/repeat time/inversion time = 2.91/2300/900 ms; slice resolution = 100%; Echo spacing = 7.7 ms, 
flip angle = 9°, field of view = 240 × 256 mm, voxel size = 1 × 1 × 1.2 mm. 
Gray matter density was quantified using unmodulated, normalized data using VBM, the VBM8 
toolbox [59] within the Statistical Parametric Mapping software (SPM8) [60] package, which was run 
via Matlab 2012a (MathWorks Inc., Natick, MA, USA). A standard protocol within VBM8 was 
followed for assessing the relationship of metacognition scores with structural characteristics. In this 
process, MRI images were first spatially normalized to the ICBM-152 standard template [61] and 
resampled to isotropic 1.5 × 1.5 × 1.5 mm voxels. An automated procedure then segmented each image 
into gray matter, white matter, and cerebrospinal fluid [28]. Normalized data were then smoothed with 
an 8-mm full-width-at-half-maximum (FWHM) isotropic Gaussian kernel. 
To quantify the relationship of gray matter density to metacognitive capacity, we conducted a 
multiple regression analysis, with age, sex (as a dummy variable), and total intracranial volume as 
regressors along with MAS-A total scores. Given that metacognition is associated with negative 
symptoms in schizophrenia [5], we conducted a separate regression, with identical regressors but also 
including PANSS negative symptom scores. A statistical threshold was set at a voxel-level p < 0.005, 
with a cluster-level family-wise error (FWE) correction of p < 0.05 to correct for multiple comparisons. 
Data from significant clusters were extracted using the MarsBaR (toolbox (http://marsbar.sourceforge.net) 
within SPM8) for visualization and post-hoc analyses with the Statistical Package for the Social 
Sciences (SPSS) 22 (IBM Corp., Armonk, NY, USA). 
4. Conclusions 
This is the first study to examine the neural correlates of metacognition, as measured by the  
MAS-A, in EPP. The present study demonstrated that increased GMD of the mPFC and VS is 
associated with higher levels of metacognition. The correlations among these areas and metacognitive 
processing fit the existing literature on the functions currently believed to be mediated by both areas. 
Such associations represent an important step in understanding the neurobiological underpinnings  
of disrupted metacognition in EPP, which ultimately culminates into poor outcomes. It also  
promotes and validates metacognition as an important treatment target in early intervention for  
psychosis and provides neurobiological marker(s) to track changes due to psychotherapeutic  
interventions (e.g., metacognitive therapy or remediation) and may lead to more accurate predictions 
of real-life/clinical outcomes. 
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